Tests LY4152199 in adults with previously treated B-cell lymphoma
Tests the drug LY4152199 in adults with B-cell lymphoma that has returned after treatment.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Seoul, South KoreaSee the 2 sitesAlso in 11 other countries, 49 sites
- Trial code
- Registry title
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 215 people, planned
- Started
- 28 May 2026
- Expected to end
- Sept 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- LY4152199 - IV
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with follicular lymphoma or diffuse large B-cell lymphoma that came back or did not respond to earlier treatment. It tests the drug LY4152199.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Follicular lymphoma or diffuse large B-cell lymphoma that came back or did not respond to treatment. Disease must be measurable. ECOG performance status 0 or 1. Life expectancy of at least 12 weeks.
- Earlier treatment
- Must have had earlier treatment. Cannot have had earlier treatment aimed at B-cell activating factor receptor (BAFF-R).
Main reasons for not taking part
- Lymphoma in the central nervous system, or a history of central nervous system disease such as stroke or epilepsy
- History of autoimmune disease or significant heart disease
- Active uncontrolled infection
- Autologous stem cell transplant within 100 days of the study
- Pregnant or planning to breastfeed during the trial or within 90 days of the last dose
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator
- Participants with select tumor types must have measurable or assessable disease as defined below:; Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement; Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (>)2 times (×) upper limit of normal (ULN) based on local laboratory testing
- Must be able to comply with inpatient/outpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation
- Must have adequate organ function; Phase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed/refractory B-cell malignancy; Phase 1 Dose Optimization (Cohort B) Participants
- Must have histologically confirmed relapsed/refractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL)
Who cannot take part
- Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia
- Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals
- Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria
- Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF)
- Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody)
- Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH)
- Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval
- History of autoimmune disease
- Significant cardiovascular disease
- Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process
- Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- Known hypersensitivity to any component or excipient of LY4152199
- Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL)
- All Participants
- Known or suspected central nervous system (CNS) involvement by systemic lymphoma
- Pregnant and/or planning to breastfeed during the trial or within 90 days of the last dose of study intervention
Where in South Korea
Also in 11 other countries, 49 sites
- Asan Medical CenterSeoul, South KoreaNot yet recruiting
- Seoul National University HospitalSeoul, South KoreaNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
The 3 groups in the trial
- Phase 1: Dose Escalation (Cohort A) - DLBCL and FLTreatment being tested
Escalating doses of LY4152199 administered intravenously (IV)
Treatment: LY4152199 - IV
- Phase 1: Dose Optimization (Cohort B1) - DLBCLTreatment being tested
Two or more doses of LY4152199 (evaluated during dose escalation) administered IV
Treatment: LY4152199 - IV
- Phase 1: Dose Optimization (Cohort B2) - FLTreatment being tested
Two or more doses of LY4152199 (evaluated during dose escalation) administered IV
Treatment: LY4152199 - IV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
- Plain-language title
- Tests LY4152199 in adults with previously treated B-cell lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026